Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III pediatric lomitapide study in homozygous familial hypercholesterolaemia
2019-002278-30Phase 3Completed
- Sponsor
- Amryt Pharma
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lomitapide in homozygous familial hypercholesterolemia (HoFH), sponsored by Amryt Pharma. Primary endpoint: Percent change from baseline in LDL-C at Week 24. Started Sep 2019; status: completed.
02
Drugs
lomitapide
03
Conditions
homozygous familial hypercholesterolemia (HoFH)
Beyond the preview
Go deeper on 2019-002278-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002278-30.